Robert W. Simms, MD
Professor
Boston University School of Medicine
Dept of Medicine
Rheumatology

MD, University of Rochester School of Medicine & Dentistry




Dr. Simms is Emeritus Professor of Rheumatology at Boston University School of Medicine. His major research interest is in scleroderma clinical outcome measures and clinical trials. He is the most active scleroderma clinician in the section, and is the site PI on multiple past and ongoing multicenter trials. He partners with Dr. Lafyatis in clinical and translational studies. This has included a recently completed trial of rituximab in systemic sclerosis. He works very closely with Dr. Farber on clinical issues as well as clinical trial initiatives in pulmonary hypertension. Dr. Simms receives NIH support as the site PI on a multi-center trial of high dose immunosuppressive therapy and autologous bone marrow transplant compared to cyclophosphamide (SCOT).

Member
Boston University
Arthritis & Autoimmune Diseases Research Center


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research




A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
05/23/2019 - 03/31/2023 (PI)
Corbus Pharmaceuticals Holdings, Inc.


Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis
09/22/2017 - 08/31/2022 (Subcontract PI)
University of Pittsburgh NIH NIAMS
5P50AR060780-07

Protocol # ML30172 - Scleroderma Lung Study III: Combining of anti-fibrotic effects of Pirfenidone with Mycophenolate to treat scleroderma-related interstitial lung disease
06/29/2018 - 02/28/2021 (PI)
University of California, Los Angeles


A Phase 1 Open-Label Study to Determine the Safety and Tolerability of AVID200, a Transforming Growth Factor B (TGFB) Inhibitor, in Patients with Diffuse Cutaneous Systemic
02/25/2019 - 02/24/2021 (PI)
Formation Biologics Corp.


Protocol # ITN075AI, (BRAVOS) - Evaluation of Brentuximab Vedotin in Diffuse Cutaneous Systemic Sclerosis
02/01/2017 - 01/31/2021 (Subcontract PI)
Benaroya Research Institute at Virginia Mason NIH NIAID
5UM1AI109565-06

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
10/18/2017 - 10/17/2020 (PI)
Corbus Pharmaceuticals Holdings, Inc.


A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Tocilizumab versus Placebo in Patients with Systemic Sclerosis
04/05/2016 - 04/30/2020 (PI)
Genentech, Inc.


Protocol #LTI-301 - A Phase 3 Open-Label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients
02/21/2018 - 02/20/2020 (PI)
Liquidia Technologies, Inc.


Dimethyl Fumarate In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
01/01/2018 - 12/31/2019 (Subcontract PI)
University of Pittsburgh NIH NIAMS
5R21AR069285-03

United States Pulmonary Hypertension Scientific Registry
10/11/2016 - 12/31/2019 (PI)
United States Pulmonary Hypertension Scientific Registry


Showing 10 of 51 results. Show All Results


Title


Yr Title Project-Sub Proj Pubs
2015 NIAMS: CORT 5P50AR060780-05 80
2015 Rheumatic Diseases Research Core Centers 5P30AR061271-05 52
2015 Core B Clinical Core 5P50AR060780-05-7136 80
2013 Core B Clinical Core 5P50AR060780-03-7136 80

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Badlam JB, Badesch DB, Austin ED, Benza RL, Chung WK, Farber HW, Feldkircher K, Frost AE, Poms AD, Lutz KA, Pauciulo MW, Yu C, Nichols WC, Elliott CG, Simms R, Fortin T, Safdar Z, Burger CD, Frantz RP, Hill NS, Airhart S, Elwing J, Marc SR, White J, Robbins IM, Chakinala MM. United States Pulmonary Hypertension Scientific Registry (USPHSR): Baseline Characteristics. Chest. 2020 Aug 25. PMID: 32858008
     
  2. Simms RW. EXPERT PERSPECTIVES ON CLINICAL CHALLENGES. Arthritis Rheumatol. 2020 Jun 20. PMID: 32562363
     
  3. Spiera R, Hummers L, Chung L, Frech TM, Domsic R, Hsu V, Furst DE, Gordon J, Mayes M, Simms R, Lafyatis R, Martyanov V, Wood T, Whitfield ML, Constantine S, Lee E, Dgetluck N, White B. Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. Arthritis Rheumatol. 2020 Apr 26.View Related Profiles. PMID: 32336038
     
  4. Khanna D, Spino C, Johnson S, Chung L, Whitfield ML, Denton CP, Berrocal V, Franks J, Mehta B, Molitor J, Steen VD, Lafyatis R, Simms RW, Gill A, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Schiopu E, Young A, Sandorfi N, Park J, Hant FN, Bernstein EJ, Chatterjee S, Castelino FV, Ajam A, Wang Y, Wood T, Allanore Y, Matucci-Cerinic M, Distler O, Singer O, Bush E, Fox DA, Furst DE. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Rheumatol. 2020 01; 72(1):125-136.View Related Profiles. PMID: 31342624
     
  5. Johnson ME, Franks JM, Cai G, Mehta BK, Wood TA, Archambault K, Pioli PA, Simms RW, Orzechowski N, Arron S, Whitfield ML. Microbiome dysbiosis is associated with disease duration and increased inflammatory gene expression in systemic sclerosis skin. Arthritis Res Ther. 2019 02 06; 21(1):49. PMID: 30728065
     
  6. Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, Pauciulo MW, Hadinnapola C, Aman J, Girerd B, Arora A, Knight J, Hanscombe KB, Karnes JH, Kaakinen M, Gall H, Ulrich A, Harbaum L, Cebola I, Ferrer J, Lutz K, Swietlik EM, Ahmad F, Amouyel P, Archer SL, Argula R, Austin ED, Badesch D, Bakshi S, Barnett C, Benza R, Bhatt N, Bogaard HJ, Burger CD, Chakinala M, Church C, Coghlan JG, Condliffe R, Corris PA, Danesino C, Debette S, Elliott CG, Elwing J, Eyries M, Fortin T, Franke A, Frantz RP, Frost A, Garcia JGN, Ghio S, Ghofrani HA, Gibbs JSR, Harley J, He H, Hill NS, Hirsch R, Houweling AC, Howard LS, Ivy D, Kiely DG, Klinger J, Kovacs G, Lahm T, Laudes M, Machado RD, MacKenzie Ross RV, Marsolo K, Martin LJ, Moledina S, Montani D, Nathan SD, Newnham M, Olschewski A, Olschewski H, Oudiz RJ, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Rehman Z, Robbins I, Roden DM, Rosenzweig EB, Saydain G, Scelsi L, Schilz R, Seeger W, Shaffer CM, Simms RW, Simon M, Sitbon O, Suntharalingam J, Tang H, Tchourbanov AY, Thenappan T, Torres F, Toshner MR, Treacy CM, Vonk Noordegraaf A, Waisfisz Q, Walsworth AK, Walter RE, Wharton J, White RJ, Wilt J, Wort SJ, Yung D, Lawrie A, Humbert M, Soubrier F, Trégouët DA, Prokopenko I, Kittles R, Gräf S, Nichols WC, Trembath RC, Desai AA, Morrell NW, Wilkins MR. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respir Med. 2019 03; 7(3):227-238. PMID: 30527956
     
  7. Hsu VM, Chung L, Hummers LK, Shah A, Simms R, Bolster M, Hant FN, Silver RM, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Saketkoo LA, Salazar CR, Steen VD. Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. J Rheumatol. 2019 02; 46(2):176-183. PMID: 30275260
     
  8. Mantero JC, Kishore N, Ziemek J, Stifano G, Zammitti C, Khanna D, Gordon JK, Spiera R, Zhang Y, Simms RW, Lafyatis R. Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial. Clin Exp Rheumatol. 2018 Jul-Aug; 36 Suppl 113(4):146-149.View Related Profiles. PMID: 30277862
     
  9. Rice LM, Mantero JC, Stratton EA, Warburton R, Roberts K, Hill N, Simms RW, Domsic R, Farber HW, Layfatis R. Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther. 2018 08 16; 20(1):185.View Related Profiles. PMID: 30115106
     
  10. Fleury M, Belkina AC, Proctor EA, Zammitti C, Simms RW, Lauffenburger DA, Snyder-Cappione JE, Lafyatis R, Dooms H. Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis. Arthritis Rheumatol. 2018 04; 70(4):566-577.View Related Profiles. PMID: 29245183
     
Showing 10 of 96 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 96 publications over 30 distinct years, with a maximum of 8 publications in 1996 and 2014 and 2016

YearPublications
19882
19901
19913
19922
19931
19946
19952
19968
19983
19992
20001
20011
20024
20031
20041
20062
20073
20081
20095
20102
20112
20122
20134
20148
20154
20168
20175
20187
20192
20203

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Scleroderma
Contact for Mentoring:

75 E. Newton St Evans Building
Boston MA 02118
Google Map


Simms's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department